Safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for adjunctive symptom relief of acute respiratory infections.
Acute bacterial respiratory infections (ABRIs) require treatment with antibiotics. Although antibiotics may address the underlying pathogenic factors, over-the-counter (OTC) agents can play an adjuvant role in relieving mucus-related symptoms. This complimentary role contributes to the healing process and is supported by current clinical guidelines.
Kikano
George
G
Department of Family Medicine, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH 44106, USA. gek@case.edu
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005100:Expectorants / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006140:Guaifenesin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000008:administration & dosage*; D054199:Pseudoephedrine / Q000008:administration & dosage*; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005100:Expectorants; D014663:Nasal Decongestants; D006140:Guaifenesin; D054199:Pseudoephedrine